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Abstract 
 
Short peptides in food protein hydrolysates are of significant interest as they may be 
highly bioactive whilst also being bioavailable. A dipeptidyl peptidase IV (DPP-IV) 
inhibitory whey protein hydrolysate (WPH) was fractionated using nanofiltration (NF) with a 
200 Da MWCO membrane. The DPP-IV half maximal inhibitory concentration of the NF 
permeate (IC50 = 0.66 ± 0.08 mg protein equivalent mL
-1
) was significantly more potent (P > 
0.05) than that of the starting WPH (IC50 = 0.94 ± 0.24 mg protein equivalent mL
-1
) and 
associated retentate (IC50 = 0.82 ± 0.13 mg protein equivalent mL
-1
). This confirmed the 
contribution of short peptides within the NF permeate to the overall DPP-IV inhibitory 
activity. An hydrophilic interaction liquid chromatography (HILIC-) and reverse-phase (RP-) 
liquid chromatography tandem mass spectrometry (LC-MS/MS) strategy, based on two 
retention time models, allowed detection of eight free amino acids and eight di- to 
tetrapeptides in the NF permeate. The potential sequences of the peptides within the NF 
permeate were then ranked on the basis of their highest probability of occurrence. A 
confirmatory study with synthetic peptides showed that valine-alanine (VA), valine-leucine 
(VL), tryptophan-leucine (WL) and tryptophan-isoleucine (WI), displayed DPP-IV IC50 
values < 170 µM. The NF and LC-MS strategy employed herein represents a new approach 
for the targeted identification of short peptides within bioactive food protein hydrolysates. 
 
 
Key words: bioactive peptides, mass spectrometry, short peptides, retention time, dipeptidyl 
peptidase IV inhibition 
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1. Introduction 
There is a growing interest in the utilisation of naturally-derived food products with 
health benefits such as antioxidant, antidiabetic and antihypertensive properties (Korhonen & 
Pilhanto, 2006; Li-Chan, 2015). Short peptide sequences are of particular interest as they 
have been associated, in certain instances, with both high bioactive potency and 
bioavailability (Segura-Campos, Chel-Guerrero, Betancur-Ancona, & Hernandez-Escalante, 
2011). This may be due to the fact that specific short peptides may be stable to 
gastrointestinal digestion and be absorbed intact in the intestinal epithelium (Foltz et al., 
2007). 
Enzymatic hydrolysis of milk proteins is a strategy frequently used for the generation 
of bioactive peptides. However, milk protein hydrolysates can contain a complex mixture of 
peptides. Therefore, fractionation of milk protein hydrolysates is employed to: (i) generate 
fractions enriched in bioactive peptides and (ii) reduce their compositional complexity, which 
may help in subsequent peptide identification. 
To date, the most frequently used techniques to separate peptides have been based on 
membrane processing and/or chromatographic separation (Bazinet & Firdaous, 2013; 
Poliwoda & Wieczorek, 2009). Nanofiltration (NF) has been utilised to enrich milk protein 
hydrolysates in bioactive peptides. It has been shown that both the molecular mass and 
peptide charge affect peptide transmission through NF membranes (Pouliot, 2008; Pouliot, 
Gauthier, & L'Heureux, 2000). 
Food protein-derived bioactive peptides can differ in length (generally < 6 amino 
acids) and physicochemical properties (Panchaud, Affolter, & Kussmann, 2012). For 
example, in the case of dietary antidiabetic peptides, several di- and tripeptides have been 
shown to be relatively potent in vitro (Lacroix & Li-Chan, 2012; Nongonierma & FitzGerald, 
2014). Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a strategy 
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commonly used to identify specific peptide sequences within food protein hydrolysates. 
However, LC-MS/MS detection of short peptides within food protein hydrolysates still 
presents several technical challenges. This is linked to the fact that a number of different 
peptide sequences can correspond to the same molecular mass. Therefore, the application of 
different separation strategies prior to MS detection can provide additional information to 
allow for short peptide identification. This is the case for chromatographic separation as 
peptide retention on a chromatographic matrix depends both on the sequence and the 
chromatographic conditions (Zou, Zhang, Hong, & Lu, 1992). The retention time of short 
peptides can be predicted using algorithm models based on properties such as peptide size 
and amino acid position within the peptide sequence (i.e., at the N-, the C-terminus or within 
the peptide sequence) (Krokhin, 2006; Le Maux, Nongonierma, & FitzGerald, 2015; Meek, 
1980; Tripet et al., 2007). Furthermore, the combination of different separation modes such 
as hydrophilic interaction liquid chromatography (HILIC) and reverse-phase (RP) 
chromatography has been shown to further enhance the accuracy of short peptide 
identification (Harscoat-Schiavo et al., 2012). 
The aim of this study was to validate a strategy involving NF, LC-MS/MS and 
retention time prediction for the selective enrichment and specific identification of short 
peptides in a bioactive protein hydrolysate. To support this approach, an antidiabetic in vitro 
bioassay measuring DPP-IV inhibition was employed. Dipeptidyl peptidase IV (DPP-IV) is a 
metabolic enzyme which has been identified in the degradation of incretins (glucose 
dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)), resulting 
in a loss in their insulinotropic properties in vivo (Juillerat-Jeanneret, 2014). To date, di- and 
tripeptide sequences have mainly been identified using in silico digestion followed by 
confirmatory studies with synthetic peptides along with peptide library approaches (Hikida, 
Ito, Motoyama, Kato, & Kawarasaki, 2013; Lan et al., 2015; Nongonierma & FitzGerald, 
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2013a; Tulipano, Sibilia, Caroli, & Cocchi, 2011). However, to our knowledge, no di- and 
tripeptides with DPP-IV inhibitory properties have to date been directly identified within 
milk protein hydrolysates using LC-MS. 
This study was carried out using a whey protein hydrolysate (WPH) with DPP-IV 
inhibitory activity. NF of the WPH was used to enrich for short peptides in the permeate. 
Milk protein-derived short peptide sequences were detected in the NF permeate and their 
overall contribution to DPP-IV inhibitory properties was assessed using a synthetic peptide 
confirmatory study. 
 
 
2. Materials and methods 
 
2.1. Reagents 
Trifluoroacetic acid (TFA), tris(hydroxymethyl)aminomethane (TRIS), Gly-Pro-pNA, 
diprotin A (IPI), porcine DPP-IV (≥ 10 units mg-1 protein), high pressure liquid 
chromatography (HPLC) and MS grade water and acetonitrile (MeCN) were obtained from 
Sigma Aldrich (Dublin, Ireland). Hydrochloric acid (HCl) and sodium hydroxide (NaOH) 
were from VWR (Dublin, Ireland). The synthetic peptides cysteine-isoleucine-valine-leucine 
(CIVL) and leucine-cysteine-valine-leucine (LCVL) were from Genscript (Piscataway, NJ, 
USA) while glycine-isoleucine (GI), leucine-glycine (LG), serine-valine (SV), tyrosine-
isoleucine (YI), tyrosine-leucine (YL), isoleucine-tyrosine (IY) and isoleucine-glycine (IG) 
were from Bachem (Bubendorf, Germany). Standard peptides (purity ≥ 95% (w/w)) used for 
the retention time prediction models were purchased from Bachem, GenScript or Thermo 
Fisher Scientific (Waltham, MA, USA) as per Le Maux et al. (2015). The whey protein 
substrate (88.3% (w/w) protein) was obtained from Carbery Food Ingredients (Ballineen, 
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Ireland). All other chemicals were obtained from Sigma Aldrich and were of analytical grade 
unless otherwise stated. 
 
2.2. Enzymatic hydrolysis of whey proteins and NF fractionation of the hydrolysate 
The WPH was generated using a food-grade pancreatic proteinase preparation at 
semi-pilot scale (200 L) as described by Nongonierma and FitzGerald (2013b). After 4 h 
hydrolysis, heat inactivation of the enzyme preparation was achieved by continuous heating 
to 85°C with 25 s holding time in a Unison H17 plate heat exchanger (Unison Engineering 
Services Ltd., Limerick, Ireland). The hydrolysate was then nanofiltered using a membrane 
housing containing a 200 Da molecular weight cut off (MWCO) spiral wound Synder 
Filtration NF membranes, NFX-2A-3838 with 31 mil spacer, at 50°C and 22 bar inlet 
operating pressure. NF was conducted until 10.5% (w/v) solids were reached in the retentate. 
Different samples were collected throughout the process (hydrolysate, 200 Da permeate and 
200 Da retentate). These were freeze-dried (FreeZone 18L, Labconco, Kansas City, U.S.A.) 
and stored at -20°C until utilization. 
 
2.3. Determination of total nitrogen 
Total nitrogen content of the WPH, NF permeate and retentate was determined in 
triplicate (n=3) by Kjeldahl analysis as previously described by Connolly, Piggott, and 
FitzGerald (2013), with a KjelFlex K-360 (BUCHI Labortechnik AG, Flawil, Switzerland). A 
conversion factor of 6.38 was used to calculate the protein equivalent in the different samples 
(Cerbulis, Woychik, & Wondolowski, 1972). 
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2.4. DPP-IV inhibition assay 
The protein hydrolysates were dispersed in HPLC-grade water at concentrations 
ranging from 31.3 × 10
-3
 to 5.0 mg mL
-1
 (final concentration). The DPP-IV inhibition assay 
was carried out as described by Nongonierma and FitzGerald (2013a). Each sample was 
analysed in triplicate. The DPP-IV half maximal inhibitory concentration (IC50) values were 
determined by plotting the percentage inhibition as a function of the concentration of test 
compound. 
 
2.5. Reverse-phase ultra-performance liquid chromatography (RP-UPLC) of the 
hydrolysates and associated NF fractions 
The peptide profiles of the different samples were determined by RP-UPLC (Acquity 
- Waters, Dublin, Ireland) equipped with a 2.1  50 mm, 1.7 µm Acquity UPLC BEH C18 
column and an Acquity BEH C18 1.7 μm vanguard pre-column (Waters) as described by 
Nongonierma and FitzGerald (2012). For each sample, 50 µg (final concentration: 5 g L
-1
, 
injection volume: 10 µL) was injected onto the column. 
 
2.6. Peptide detection with liquid chromatography-mass spectrometry (LC-MS/MS) 
Samples were analysed by LC-MS/MS using a UPLC system (Waters) coupled to a 
quadrupole time-of-flight mass spectrometer (Impact HD™, Bruker Daltonics GmbH, 
Bremen, Germany). The MS was equipped with an electrospray ionisation (ESI) source used 
in positive ion mode. Instrument control and data acquisition were performed using Hystar™ 
software (Bruker Daltonics). 
Two complementary chromatographic modes were used for peptide separation prior 
to MS/MS analysis. RP and HILIC separations were used as compounds elute differently on 
these two matrices. RP-UPLC was performed using an Acquity BEH C18 column (2.1 x 150 
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mm, 1.7 µm) equipped with an Acquity BEH C18 1.7 μm vanguard pre-column (Waters). 
Mobile phase A was 0.1% (v/v) TFA in water whereas mobile phase B was 0.1% (v/v) TFA 
in MeCN. A linear gradient from 100 to 60% solvent A was applied for 120 min at a flow 
rate of 0.2 mL min
-1
. The column temperature was maintained at 40ºC. Samples were diluted 
in solvent A (final concentration of 5 g L
-1
) and filtered through 0.2 µM cellulose acetate 
filters before injection (2 µL). The UPLC system was equipped with a tunable UV detector 
set at 214 and 280 nm. The operating conditions were initially investigated to obtain the 
optimal separation of a complex milk protein hydrolysate sample. MS measurements were 
performed over a 70-700 m/z acquisition range. MS data were processed on Compass 
DataAnalysis 4.0 SP5 (Bruker Daltonics). 
HILIC chromatography was performed on an Acquity BEH amide column as 
previously described by Le Maux et al. (2015). The MS operating conditions were similar to 
those described above for RP-LC-MS/MS. 
 
2.7. Retention time prediction models and identification of short peptides by LC-MS  
Retention time prediction models were coupled to MS/MS data in order to improve 
peptide identification. The HILIC retention time model used was as described by Le Maux et 
al. (2015). Another model based on RP separation was developed herein using a similar 
strategy. Briefly, a training set of 153 standard peptides was used to determine the algorithm 
of the RP prediction model. These peptides were selected based on their range of 
hydrophilicity/hydrophobicity, peptide size (di- to tetrapeptides) and sequence. Matlab 
(version 2014b, The MathWorks Inc., Natick, MA, USA) was used to generate coefficients 
representing the impact of each amino acid on peptide apparent hydrophobicity. These 
hydrophobicity coefficients were determined depending on amino acid location (C-, N-
terminus or within the peptide sequence). The apparent hydrophobicity of a peptide (H) was 
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determined as the sum of each amino acid coefficient in the peptide chain (Meek, 1980). 
Subsequently, a linear regression was performed to predict retention time using both peptide 
sequence and length. The RP retention time model was statistically validated as previously 
described (Le Maux et al., 2015). 
The approach to identify short peptides within the nanofiltrate was also as described 
by Le Maux et al. (2015). A list of potential peptides, which corresponded to the properties of 
the detected peptides, was generated using a mass tolerance set at 0.1 Da. An in-house bovine 
milk protein database was built in order to discard non relevant peptides using all the 
available genetic variants, given in PubMed, of the major bovine milk proteins (β-
lactoglobulin, α-lactalbumin, bovine serum albumin, lactoferrin, αs1-, αs2-, β- and κ-casein). 
As several peptide sequences could correspond to the retention time and molecular mass of 
one peptide signal, these potential peptides were ranked as a function of their retention time 
differences (observed minus predicted retention times). 
 
2.8. Statistical analysis 
Means comparison was carried out using a one way ANOVA. Post-hoc tests were 
conducted following a Student Newman-Keuls test using SPSS (version 22, SPSS Inc., 
Chicago, IL, USA) at a significance level P < 0.05. 
 
 
3. Results 
 
3.1. Peptide profile of the WPH and associated NF fractions 
The RP-UPLC profiles for the WPH and its associated NF retentate and permeate are 
depicted in Fig. 1. The WPH and its NF retentate had similar peptide profiles showing a large 
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number of peptide peaks eluting during the first 25 min of the MeCN gradient. In contrast, 
the NF permeate shows a less complex profile, with 3 main peaks eluting at 2.9, 4.8 and 7.7 
min. Similar peaks were also present in the WPH and the NF retentate, but at a lower 
intensity in the WPH than in the NF permeate. 
 
3.2. DPP-IV inhibitory activity of the WPH and associated NF fractions 
The DPP-IV IC50 values were 0.94 ± 0.24, 0.82 ± 0.13 and 0.66 ± 0.08 mg protein 
equivalent mL
-1
 for the WPH, NF retentate and permeate, respectively (Table 1). The DPP-IV 
IC50 for the NF permeate was significantly lower (P < 0.05) than that of the WPH and NF 
retentate. 
The NF permeate peptide profile showed a significantly reduced complexity (i.e., 
three main peptide peaks, Fig. 1). In addition, it displayed the highest DPP-IV inhibitory 
potency (Table 1). Therefore, LC-MS/MS analysis was applied to the NF permeate with a 
view to specifically identify short peptides contributing to the overall DPP-IV inhibitory 
properties of the WPH. 
 
3.3. Development of the reverse phase (RP) retention time prediction (RTpred) model 
The retention time prediction (RTpred) model was best described by the equation: 
          (Equation 1) 
The constants a and b were optimised through iterations of the amino acid 
hydrophobic coefficients and were defined in the operating conditions as - 1.384 ± 0.194 and 
0.9383 ± 0.006, respectively. The established amino acid hydrophobic coefficients that 
allowed equation 1 to have the highest R
2 
are described in Supplementary Table S1. The 
peptide apparent hydrophobicity (H) was calculated using these coefficients. Tryptophan (W) 
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had the highest hydrophobic coefficients, followed by phenylalanine (F) > leucine (L) and 
isoleucine (I) > tyrosine (Y), methionine (M) and valine (V). The basic and polar with 
uncharged side group amino acids exerted a very low influence on the retention time. 
However, depending on their position in the peptide sequence, some of these amino acids 
displayed a large difference between their hydrophobic coefficients. For instance, the 
hydrophobic coefficients for threonine (T) were low but displayed large variations (from -
5.387 to 5.563 in C- and N-terminus, respectively) compared to W coefficients which were 
high but varied within a narrow range (from 25.659 to 28.989 in N- and C-terminus, 
respectively). The position of some amino acids in the peptide sequence had an impact on the 
retention time. Indeed, twenty-five pairs of homologous peptides (peptides with the same 
amino acid composition but in a different sequence) were analysed, nineteen of these peptides 
had significantly (P < 0.05) different retention time (data not shown). For example, the 
dipeptides WD and DW had retention times of 22.076 ± 0.077 and 33.477 ± 0.019 min, 
respectively. There were no peptides eluting before 2.1 min, which represented the void 
volume of the column. 
The RP retention time model was statistically validated, having an R
2
 of 0.978, a F-
statistic of 2.23 × 10
4
 with an extremely low P-value (P < 5 × 10
-324
) and a Durbin–Watson 
statistic value of 1.762. The Cook’s distance and the residual plots of this prediction model 
were considered acceptable as no outliers could be determined (data not shown). The root 
mean squared error of the model, as well as the root mean squared errors of two cross-
validations, leave-one-out and tenfold cross-validations, revealed the robustness of the model 
as the values were of 2.724, 2.992 and 2.995, respectively. The predicted retention time had 
intervals of 6.8 and 8.4 min for confidence levels of 95 and 99%, respectively (Fig. 2). 
Therefore, a 10 min difference interval between the observed and predicted retention times 
was used as a cut off to select the possible peptide candidates. 
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3.4. Identification of peptides within the NF permeate of the WPH 
A relatively low number (16) of compounds could be detected by LC-MS/MS within 
the NF permeate (Table 2). For the first time, the peptides of this NF permeate sample were 
subsequently identified. These compounds were analysed by correlating their molecular 
mass, retention time and MS/MS spectrum. As several sequences could match the properties 
of one compound, these sequences were defined as potential peptides within the NF 
permeate. The presence of potential peptide sequences was searched against an in-house 
bovine milk protein database in order to reject non-relevant peptides. Eight amino acids, 
seven dipeptides and one tetrapeptide were detected within the NF permeate. The potential 
peptide sequences were ranked based on their highest probability of occurrence (Table 2). 
This was achieved by using the two retention time models (RP and HILIC) to allow for a 
more accurate ranking of homologous peptides. For instance, the molecular mass of peptide 
No. 10 in Table 2 corresponded to 6 (GI, GL, IG, LG, AV and VA) potential peptide 
sequences, but only 5 (GI, GL, IG, LG and AV) of these had predicted retention times that 
were within 10 min of the observed peptide retention time. Moreover, these potential peptides 
were ranked based on their retention time differences (predicted versus observed retention 
times), with GI and GL having the highest probability, followed by IG and LG, and then AV. 
VA was excluded as a potential peptide candidate for compound No. 10 as the difference 
between its predicted and observed retention time in RP conditions was > 10 min. Y, F and 
W showed the highest intensities by UV detection at 214 nm in HILIC-MS/MS and RP-
MS/MS, which is in accordance with the peptide profile in Fig. 1 where these aromatic amino 
acids eluted at 2.9, 4.8 and 7.7 min, respectively. 
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3.5. Confirmatory study of DPP-IV inhibitory activity with synthetic peptides 
Several of the peptide sequences identified within the NF permeate have previously 
been identified in the literature (Table 2). Therefore, only the peptide sequences which had 
not previously been reported for their DPP-IV inhibitory properties were synthesised for 
further confirmatory study. It was conducted to determine which compounds within the NF 
permeate were bioactive. Previously published DPP-IV IC50 values for the amino acids which 
were found within the NF permeate are shown in Table 3 (Nongonierma, Mooney, Shields, & 
FitzGerald, 2013). In addition, IW, LW, WL, WI VA, GL, FW, WF and VL have also been 
previously evaluated for their DPP-IV inhibitory potential (Lan, Ito, Ito, & Kawarasaki, 2014; 
Lan et al., 2015; Nongonierma & FitzGerald, 2013a, 2013d; Tulipano et al., 2011). Three 
peptides reported for the first time (CIVL, LCVL and GI) were evaluated for their in vitro 
DPP-IV inhibitory properties in this study (Table 2). Their DPP-IV IC50 values are reported 
in Table 3. WL was the most potent DPP-IV inhibitory peptide identified within the NF 
permeate, with an IC50 value of 43.6 µM. The NF permeate contained four potential DPP-IV 
inhibitory peptides, VL, VA, WL and WI with IC50 values < 170 µM. 
 
 
4. Discussion 
 
The fractionation of complex peptide mixtures followed by the identification of 
bioactive peptides is of major interest as it allows further optimisation of the protein 
hydrolysis processes, with the view of increasing the potency of bioactive ingredients. The 
NF and LC-MS/MS approach describe herein allowed for the development of an integrated 
strategy aimed at the identification of potent short DPP-IV inhibitory peptides within a WPH. 
Previous studies have identified short milk protein-derived peptides within milk protein 
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hydrolysate fractions (Lacroix & Li-Chan, 2014; Silveira, Martínez-Maqueda, Recio, & 
Hernández-Ledesma, 2013). However, the peptides reported were  4 amino acid residues in 
length. To our knowledge, it is the first time that di and tripeptides are identified using LC-
MS/MS within a milk protein hydrolysate fraction. 
Identification of short peptide sequences in complex food protein hydrolysates is 
challenging. Therefore, a new RP retention time prediction model focused on short peptide 
(up to four amino acids in length) separation was developed. It was based on the amino acid 
location within a peptide and its impact on peptide apparent hydrophobicity. Previous studies 
have also highlighted the impact of N- and C-terminal amino acids on the retention time of 
peptides in RP conditions (Krokhin, 2006; Tripet et al., 2007). These studies showed a similar 
trend to the model herein concerning the influence of each residue on peptide hydrophobicity 
with W, F, L and I having the highest impact. Interestingly, the elution order of peptides 
under RP and HILIC conditions were not the mirror image of each other as the contribution 
of each amino acid to the RP retention time was not the exact opposite of their contribution in 
HILIC conditions (Le Maux et al., 2015). Therefore, the differences between the two 
separation modes showed that HILIC- and RP-LC were complementary peptide separation 
methods. The use of complementary separation methods has previously been shown to 
significantly enhance peptide identification (Harscoat-Schiavo et al., 2012). Peptide 
identification was improved herein by focusing on di- to tetrapeptides and discriminating on 
the basis of the amino acid position within the peptide chain. This peptide identification 
strategy permitted the compilation of a short ranked list of potential sequences for the 
unknown peptides detected in the NF permeate (Table 2). 
Previous fractionation studies were performed on the WPH fractionation using a 2 
kDa ultrafiltration membrane and an hydrophobic solid-phase extraction (SPE) resin 
(Nongonierma & FitzGerald, 2013b). When the SPE fraction was analysed by LC-MS/MS in 
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the previous study, 45 potential peptides were identified. However, this number of potential 
peptide candidates was too high to distinguish which peptide sequence(s) may be responsible 
for the DPP-IV inhibitory properties (Le Maux et al., 2015). The NF fractionation approach 
described herein allowed the generation of a fraction with a reduced complexity (16 
compounds) and a significant higher DPP-IV inhibitory activity than the WPH. While the 
IC50’s of the different samples were of the same order, this approach demonstrated that short 
peptides were responsible in part for the bioactivity of the WPH. This NF permeate fraction 
was characterised in the present study for the first time. The masses of the compounds 
detected in the NF permeate were compatible with the nominal MWCO of the membrane as it 
contained free amino acids and short peptides (2-4 amino acid in length). As the permeation 
of compounds through the membrane is dependant of the NF conditions (i.e., pressure, 
temperature, etc.) as well as the peptide conformation, it may explain the detection of a 
447.295 Da peptide in the permeate. As this study focused on short peptides, the NF permeate 
was the only sample which was further characterised by LC-MS/MS. Moreover, the NF 
permeate was the most potent fraction and displayed a reduced peptide profile complexity.  
The DPP-IV inhibitory properties of three amino acids found within the NF permeate 
(L, M and W) had previously been demonstrated. However, their DPP-IV inhibitory potency 
was quite low (IC50 > 2300 µM (Nongonierma et al., 2013)). The most potent peptides (IC50 
< 170 µM) found within the NF permeate of WPH were WI, WL, VA and VL. This result 
was in agreement with a previous in silico study using a peptide alignment strategy, which 
showed that peptides possessing a W at the N-terminus and/or a P at position 2 generally had 
DPP-IV IC50’s < 200 µM (Nongonierma & FitzGerald, 2014). Interestingly, WL (IC50 = 43.6 
µM), the most potent peptide within the NF permeate sample was of the same order of DPP-
IV inhibitory potency as LKPTPEGDL (IC50 = 45 µM) and IPAVF (IC50 = 44.7 µM), which 
had previously been identified within whey protein hydrolysates (Lacroix & Li-Chan, 2014; 
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Silveira et al., 2013). It was shown in previous studies that specific milk protein-derived 
peptides with a DPP-IV IC50 value of the same order as the most potent peptides identified 
within the NF permeate displayed an antidiabetic activity in vivo. This was the case with the 
DPP-IV inhibitory peptides VAGTWY (β-lactoglobulin f15-20; IC50 = 174 µM) and 
LPQDIPPL (β-casein f70–77; IC50 = 46 µM) which mediated insulinotropic and serum 
glucose lowering activities in small animals (Uchida, Ohshiba, & Mogami, 2011; Uenishi, 
Kabuki, Seto, Serizawa, & Nakajima, 2012). The results presented herein need to be assessed 
in vivo in order to understand how they may affect serum glucose regulation. 
The interest in focusing on short (di- tri and tetra-) peptides was related to the fact that 
these sequences may be bioavailable as they may be able to survive gastrointestinal digestion 
and also display an increased intestinal permeability compared to larger peptides or free 
amino acids. Permeation of short peptides (di- and tripeptides) through Caco-2 cell 
monolayers has been reported in in vitro studies (Shimizu, Tsunogai, & Arai, 1997). Human 
studies have also shown that short peptides have the ability to cross the gut barrier as they 
were identified in the serum following the ingestion of a yoghurt enriched in the 
lactotripeptides, LPP and VPP (Foltz et al., 2007), or milk protein hydrolysates (Morifuji et 
al., 2010). In silico digestion of the most potent peptides (VL, VA, WL and WI) indicated 
that VA and VL may be stable to digestion with gastrointestinal enzymes as described in 
Nongonierma and FitzGerald (2013c) (data not shown). However, confirmatory in vitro and 
in vivo studies are required to support these results. 
 
 
5. Conclusion 
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A new strategy to identify short peptides was developed, being innovative in the 
utilisation of a RP and HILIC approach designed for di- to tetrapeptides. This new approach 
allowed the differentiation between homologous peptides. This method was optimised to 
identify short peptides which cannot usually be identified by MS/MS and de novo searches. 
The use of further separation methods prior to MS, such as ion-exchange or capillary 
electrophoresis, may lead to the determination of a unique peptide sequence for each 
compound detected. 
To our knowledge, NF has not been previously employed during the fractionation and 
further identification of DPP-IV inhibitory peptides from complex food protein hydrolysate 
samples. Specific short peptide sequences found within the NF permeate of the WPH were 
shown to be relatively potent DPP-IV inhibitory peptides (IC50 < 170 µM). This 
demonstrated that short peptides were also responsible for the overall DPP-IV inhibitory 
potential of the WPH. Furthermore, these peptides were predicted in silico to be relatively 
stable to gastrointestinal digestion. However, these results need to be confirmed following in 
vitro and in vivo digestion of the fraction.  
The results reported in this study demonstrated that, with the strategy employed, it 
was possible to improve the fractionation and subsequently the detection of short DPP-IV 
inhibitory peptides in a milk protein hydrolysate. The strategy described herein is highly 
relevant to the discovery of short bioactive peptide sequences.
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Figure captions 
 
Fig. 1. Reverse-phase ultra-performance liquid chromatographic (RP-UPLC) profile 
of (A) the whey protein hydrolysate (WPH), (B) its associated 200 Da retentate and (C) 
permeate. MeCN: acetonitrile. The amino acids Y, F and W elute at 2.9, 4.8 and 7.7 min, 
respectively. 
 
Fig. 2. Plot of predicted versus observed retention times of the set of 153 training 
peptides. The observed retention times (RTobs) corresponds to the mean of three replicates (n 
= 3). Peptide trendline, black solid line; confidence limits of the prediction at 95%, black 
dashed line; confidence limits of the prediction at 99%, grey solid line. 
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Table captions 
 
Table 1 Dipeptidyl peptidase IV (DPP-IV) inhibitory potency (concentration of 
sample inducing 50% DPP-IV inhibition - IC50) of the whey protein hydrolysate (WPH) and 
its associated nanofiltration (NF) retentate and permeate. 
 
Table 2 Peptide and free amino acid identification in the nanofiltration (NF) whey 
protein hydrolysate (WPH) permeate using the in-house milk protein database and the reverse 
phase (RP) and hydrophilic interaction liquid chromatography (HILIC) retention time 
prediction models. The number of possible compounds was based on the Mw determined 
experimentally by LC-MS/MS with an error of 0.1 Da. 
 
Table 3 Concentration of peptides, identified within the nanofiltration (NF) whey 
protein hydrolysate (WPH) permeate, inducing 50% inhibition (IC50) of dipeptidyl peptidase 
IV (DPP-IV). 
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Table 1 
 
Test sample DPP IV IC50 
(mg protein equivalent mL
-1
)
*
 
WPH 0.94 ± 0.24
b
 
WPH NF retentate 0.82 ± 0.13
b
 
WPH NF permeate 0.66 ± 0.08
a
 
 
*Values represent mean IC50 values ± confidence interval (P = 0.05), n=3. Values 
with different superscript letters are significantly different (P < 0.05). The DPP-IV 
IC50 of IPI (diprotin A) was of 0.0013 ± 0.0002 mg mL
-1
. 
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Table 2 
 
Peptide 
No. 
Mw+H 
(Da) 
No. of 
peptides with 
the targeted 
Mw 
No. of potential 
sequences after the 
models and milk 
database 
Potential sequences 
(ranked in peptide 
order)* 
Sequences previously 
assessed for their DPP-
IV inhibition** 
1 118.086 1 1 V V 
2 132.101 2 2 I, L I, L 
3 132.101 2 2 I, L I, L 
4 150.058 1 1 M M 
5 166.086 1 1 F F 
6 175.118 3 1 R R 
7 182.080 1 1 Y Y 
8 189.122 6 4 AV, VA > IG, GI AV, VA 
9 189.122 6 4 AV, VA > IG, GI AV, VA 
10 189.122 
6 5 GI, GL > IG, LG > 
AV 
GL, LG, AV 
11 205.096 7 1 W W 
12 231.168 6 4 IV, VI, LV, VL IV, VI, LV, VL,  
13 295.165 6 4 IY, YI, LY, YL YI, LY, YL 
14 318.182 105 4 IW, WI, LW, WL IW, WI, LW, WL 
15 447.295 1082 2 CIVL > LCVL - 
 
* Sequences separated by a comma have the same probability of occurrence, whereas “>” showed the 
sequences with higher probability of occurrence. Novel peptides selected for the DPP-IV inhibitory 
confirmatory study are highlighted in bold. 
** Peptides previously identified for their DPP-IV inhibitory properties as described elsewhere (Lan et al., 
2015; Nongonierma & FitzGerald, 2014). 
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Table 3 
Peptide sequence /amino 
acid 
DPP IV IC50 
(M)* 
Reference 
V nm (Nongonierma et al., 2013) 
L 3419.25 (Nongonierma et al., 2013) 
I nm (Nongonierma et al., 2013) 
M 2381.51 (Nongonierma et al., 2013) 
F nm (Nongonierma et al., 2013) 
W 4280.40 (Nongonierma et al., 2013) 
R nm (Nongonierma et al., 2013) 
Y nm (Nongonierma et al., 2013) 
IPI 3.73 ± 0.67
a
 this study 
CIVL nm this study 
LCVL nm this study 
IW nm (Nongonierma et al., 2013) 
LW 993.4 (Nongonierma & FitzGerald, 2013c) 
WL 43.6 (Nongonierma & FitzGerald, 2013c) 
WI 138.7 (Nongonierma & FitzGerald, 2013c) 
VA 168.2 (Nongonierma & FitzGerald, 2013a) 
AV nm (Lan et al., 2015) 
IG nm this study 
GI nm this study, (Lan et al., 2015) 
GL 2615 (Nongonierma & FitzGerald, 2013a) 
LG nm this study, (Lan et al., 2015) 
YI 1488.50 ± 
229.79
c
 
this study 
 nm (Lan et al., 2015) 
YL 940.20 ± 279.00
b
 this study 
 nm (Lan et al., 2015) 
IV nm (Lan et al., 2015) 
VI nm (Lan et al., 2015) 
LV nm (Lan et al., 2015; Tulipano, Sibilia, Caroli, 
& Cocchi, 2011) 
VL 74 (Lan et al., 2014) 
IY nm this study 
LY nm (Lan et al., 2015) 
 
*Values represent mean IC50 values ± confidence interval (P = 0.05), n=3. Values with a 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
32 
different superscript letters are significantly different (P < 0.05). nd: not determined; nm: not 
measureable, i.e.,% DPP-IV inhibition < 50% when tested at the highest concentration 
evaluated during the dose response experiment. 
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Highlights 
 Nanofiltration (NF) was used to fractionate a whey protein hydrolysate (WPH). 
 An HILIC and RP-UPLC peptide retention time model was developed. 
 This strategy allowed characterisation of short peptides within the NF permeate. 
 DPP-IV inhibitory activity was increased in the NF permeate compared to WPH. 
 VA, VL, WL and WI displayed DPP-IV IC50 values lower than 170 µM. 
